XML 117 R46.htm IDEA: XBRL DOCUMENT v3.20.1
SHAREHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Schedule of Shareowners' Equity
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Three months ended March 31
(In millions)
2020

 
2019

 
 
 
 
Beginning balance
$
61

 
$
(39
)
Other comprehensive income (loss) (OCI) before reclassifications – net of deferred taxes of $0 and $38(a)
6

 
28

Reclassifications from OCI – net of deferred taxes of $(12) and $(1)
(47
)
 
(4
)
Other comprehensive income (loss)
(41
)
 
24

Less OCI attributable to noncontrolling interests
—

 
1

Investment securities ending balance
$
20

 
$
(16
)
 
 
 
 
Beginning balance
$
(4,818
)
 
$
(6,134
)
OCI before reclassifications – net of deferred taxes of $(5) and $26
(554
)
 
307

Reclassifications from OCI – net of deferred taxes of $0 and $(4)(b)
690

 
117

Other comprehensive income (loss)
135

 
423

Less OCI attributable to noncontrolling interests
2

 
100

Currency translation adjustments ending balance
$
(4,685
)
 
$
(5,810
)
 
 
 
 
Beginning balance
$
49

 
$
13

OCI before reclassifications – net of deferred taxes of $(45) and $11
(262
)
 
34

Reclassifications from OCI – net of deferred taxes of $8 and $(4)(b)
51

 
3

Other comprehensive income (loss)
(211
)
 
38

Less OCI attributable to noncontrolling interests
—

 
2

Cash flow hedges ending balance
$
(163
)
 
$
49

 
 
 
 
Beginning balance
$
(7,024
)
 
$
(8,254
)
OCI before reclassifications – net of deferred taxes of $30 and $48
219

 
(116
)
Reclassifications from OCI – net of deferred taxes of $239 and $183(b)
817

 
662

Other comprehensive income (loss)
1,035

 
545

Less OCI attributable to noncontrolling interests
3

 
(2
)
Benefit plans ending balance
$
(5,991
)
 
$
(7,708
)
 
 
 
 
Accumulated other comprehensive income (loss) at March 31
$
(10,819
)
 
$
(13,485
)

(a) Included adjustments of $1,267 million and $(957) million for the three months ended March 31, 2020 and 2019, respectively related to insurance liabilities and annuity benefits in our run-off insurance operations to reflect the effects that would have been recognized had the related unrealized investment security gains been realized. See Note 12 for further information.
(b) Included $836 million, including currency translation of $688 million, net of taxes, for the three months ended March 31, 2020, related to the sale of our BioPharma business within our Healthcare segment.